1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings

Bibliographic Details
Main Author: Jun Ishihara
Format: Article
Language:English
Published: BMJ Publishing Group 2023-11-01
Series:Journal for ImmunoTherapy of Cancer
_version_ 1797630654913970176
author Jun Ishihara
author_facet Jun Ishihara
author_sort Jun Ishihara
collection DOAJ
first_indexed 2024-03-11T11:11:14Z
format Article
id doaj.art-1e70156a7b42418494ebdd8e49a6ca87
institution Directory Open Access Journal
issn 2051-1426
language English
last_indexed 2024-03-11T11:11:14Z
publishDate 2023-11-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj.art-1e70156a7b42418494ebdd8e49a6ca872023-11-12T04:00:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.12131213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settingsJun Ishihara01Imperial College London, London, UK
spellingShingle Jun Ishihara
1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings
Journal for ImmunoTherapy of Cancer
title 1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings
title_full 1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings
title_fullStr 1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings
title_full_unstemmed 1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings
title_short 1213 Tumor-ECM targeted IL-12: improved safety and efficacy in clinically relevant settings
title_sort 1213 tumor ecm targeted il 12 improved safety and efficacy in clinically relevant settings
work_keys_str_mv AT junishihara 1213tumorecmtargetedil12improvedsafetyandefficacyinclinicallyrelevantsettings